List price and what drives it
Foundayo's list price at launch is approximately $695/month for a 30-day supply at the maintenance 36 mg dose. List price is what an uninsured patient sees at the retail pharmacy counter before discounts.
Lilly positioned this price aggressively. Comparable branded injectables (Wegovy ~$1,350, Zepbound ~$1,060) cost meaningfully more. The pricing reflects two factors: (1) orforglipron is a small molecule, cheaper to manufacture than peptide injectables, and (2) Lilly wants to capture market share in the oral GLP-1 segment before the inevitable generic semaglutide arrives in 2028-2029.
LillyDirect: $349-499/month for self-pay
Lilly's direct-to-patient pharmacy (LillyDirect.com) offers Foundayo at $349-499/month for self-pay patients. Pricing tiers by quantity:
| Supply | Cost | Per month |
|---|---|---|
| 30-day | $499 | $499 |
| 60-day | $899 | $449 |
| 90-day | $1,049 | $349 |
LillyDirect requires a valid US prescription. You can order through their site or have a telehealth provider (such as Ro or Hims) coordinate with LillyDirect for fulfillment.
Commercial insurance: $25-100 copay
Most large commercial plans (Aetna, Cigna, BCBS variants, UnitedHealthcare) have added Foundayo to their formularies through 2026. Coverage typically requires:
- BMI ≥30 (obesity), OR BMI ≥27 with at least one weight-related comorbidity
- Prior authorization documentation submitted by your prescriber
- Some plans require documented prior lifestyle intervention (3-6 months of diet/exercise)
Approved copays typically run $25-100/month depending on your plan tier. The Lilly manufacturer savings card can further reduce copay to $25 maximum for eligible commercially-insured patients.
Medicare GLP-1 Bridge: $50/month from July 1
The Medicare GLP-1 Bridge program (effective July 1, 2026) covers Foundayo at $50/month copay for eligible Medicare Part D beneficiaries. Eligibility: BMI ≥30, or BMI ≥27 with a qualifying comorbidity.
The Bridge is a demonstration program running through December 31, 2027. See our Medicare GLP-1 Bridge complete guide for enrollment details.
State Medicaid coverage
13 state Medicaid programs cover GLP-1s for obesity as of mid-2026, including Foundayo once individual state plans add it to formularies (rolling out through Q3 2026):
- ✅ California
- ✅ Connecticut
- ✅ Delaware
- ✅ Kansas
- ✅ Massachusetts
- ✅ Minnesota
- ✅ New Hampshire
- ✅ North Carolina
- ✅ Pennsylvania
- ✅ Rhode Island
- ✅ Vermont
- ✅ Virginia
- ✅ Wisconsin
Eliminated coverage in 2025: Iowa, Texas, Florida, Georgia. If you live in one of these states, Medicare Bridge (if eligible) or LillyDirect cash-pay are your alternatives.
Find the cheapest provider for Foundayo
Telehealth providers add provider fees on top of medication cost. See our ranking of cheapest providers carrying Foundayo.
See cheapest providers →Frequently asked questions
- How much does Foundayo cost without insurance?
- List price is approximately $695/month at retail pharmacies. Eli Lilly's LillyDirect cash-pay program offers Foundayo at $349-499/month for self-pay patients ordering direct.
- Does insurance cover Foundayo?
- Yes, increasingly. Most commercial plans cover Foundayo with prior authorization for patients meeting BMI criteria (≥30 or ≥27 with comorbidity). Copay typically $25-100/month.
- Does Medicare cover Foundayo?
- Yes, starting July 1, 2026 via the Medicare GLP-1 Bridge demonstration program at $50/month copay. Coverage runs through December 31, 2027.
- Are there coupons or savings cards for Foundayo?
- Eli Lilly offers a manufacturer savings card that can reduce out-of-pocket cost to $25-50/month for commercially insured patients. Check the Foundayo official site for eligibility.
- Is compounded orforglipron cheaper?
- No. Orforglipron is a small-molecule drug under active FDA exclusivity. Unlike injectable GLP-1s, it has not been the subject of large-scale compounding. Branded LillyDirect is the lowest legitimate cash-pay path.
- Why is Foundayo cheaper than injectable GLP-1s?
- Two factors: smaller molecule (simpler manufacturing than peptides) and competitive launch pricing — Lilly positioned Foundayo aggressively against injectables and oral Wegovy to capture market share.
Pricing verified: May 24, 2026. Prices change frequently; verify current rates directly with the pharmacy or LillyDirect before relying on these figures. Affiliate disclosure: provider links may be sponsored. Editorial content reviewed by Jane Novak, MD, MPH.